Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Recombinant activated factor VII in cardiac surgery: single-center experience.

Singh SP, Chauhan S, Choudhury M, Malik V, Choudhary SK.

Asian Cardiovasc Thorac Ann. 2014 Feb;22(2):148-54. doi: 10.1177/0218492312471672.

PMID:
24585784
2.

Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.

Uber WE, Toole JM, Stroud MR, Haney JS, Lazarchick J, Crawford FA Jr, Ikonomidis JS.

J Thorac Cardiovasc Surg. 2011 Jun;141(6):1469-77.e2. doi: 10.1016/j.jtcvs.2011.02.033.

3.

Intraoperative use of recombinant activated factor VII during complex aortic surgery.

Goksedef D, Panagopoulos G, Nassiri N, Levine RL, Hountis PG, Plestis KA.

J Thorac Cardiovasc Surg. 2012 May;143(5):1198-204. doi: 10.1016/j.jtcvs.2012.01.004.

4.

Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ.

J Cardiothorac Vasc Anesth. 2011 Dec;25(6):987-94. doi: 10.1053/j.jvca.2011.05.012.

PMID:
21835642
5.

Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).

Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP.

Eur J Cardiothorac Surg. 2011 Dec;40(6):1320-7. doi: 10.1016/j.ejcts.2011.03.032.

PMID:
21550261
6.

Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.

Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS.

Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7. doi: 10.1016/j.athoracsur.2008.01.089.

PMID:
18442563
7.

Factor VII for excessive bleeding following congenital heart disease surgery.

Changlani DK, Devendaran V, Murmu UC, Ganesan S, Varghese R, Kumar RS.

Asian Cardiovasc Thorac Ann. 2012 Apr;20(2):120-5. doi: 10.1177/0218492311433614.

PMID:
22499956
8.

Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.

Guzzetta NA, Russell IA, Williams GD.

Anesth Analg. 2012 Aug;115(2):364-78. doi: 10.1213/ANE.0b013e31825aff10. Review.

PMID:
22652310
9.

Recombinant activated factor VII for hemorrhage after pediatric cardiac surgery.

Singh SP, Chauhan S, Choudhary M, Vasdev S, Talwar S.

Asian Cardiovasc Thorac Ann. 2012 Feb;20(1):19-23. doi: 10.1177/0218492311432584.

PMID:
22371937
10.

Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.

Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH.

Ann Thorac Surg. 2006 Nov;82(5):1779-83.

PMID:
17062247
11.

Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.

Tatoulis J, Theodore S, Meswani M, Wynne R, Hon-Yap C, Powar N.

Interact Cardiovasc Thorac Surg. 2009 Sep;9(3):459-62. doi: 10.1510/icvts.2009.204735.

12.

Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: a single institution experience.

Karsies TJ, Nicol KK, Galantowicz ME, Stephens JA, Kerlin BA.

Ann Thorac Surg. 2010 Feb;89(2):570-6. doi: 10.1016/j.athoracsur.2009.11.023.

PMID:
20103344
13.

Pediatric off-label use of recombinant factor VIIa.

Alten JA, Benner K, Green K, Toole B, Tofil NM, Winkler MK.

Pediatrics. 2009 Mar;123(3):1066-72. doi: 10.1542/peds.2008-1685.

PMID:
19255041
14.

Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.

von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, Spies C.

Crit Care Med. 2005 Oct;33(10):2241-6.

PMID:
16215377
15.

Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Transfusion. 2013 Apr;53(4):798-804. doi: 10.1111/j.1537-2995.2012.03801.x.

PMID:
22845023
16.

Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.

Pham HP, Hsu SX, Parker-Jones S, Samstein B, Diuguid D, Schwartz J.

Vox Sang. 2014 Jan;106(1):75-82. doi: 10.1111/vox.12067.

PMID:
23815226
17.

Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?

Okonta KE, Edwin F, Falase B.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):690-4. Review.

18.

Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.

Gelsomino S, Lorusso R, Romagnoli S, Bevilacqua S, De Cicco G, Billè G, Stefàno P, Gensini GF.

Eur J Cardiothorac Surg. 2008 Jan;33(1):64-71.

PMID:
17996457
19.

Decreasing the need for transfusion: infant cardiac surgery using hemodilution and recombinant factor VIIa.

Winch PD, Naguib AN, Bradshaw JR, Galantowicz M, Tobias JD.

Pediatr Cardiol. 2013 Jan;34(1):119-24. doi: 10.1007/s00246-012-0398-1.

PMID:
22760694
20.

The danger of using a sledgehammer to crack a nut: ROTEM-guided administration of recombinant activated factor VII in a patient with refractory bleeding post-ventricular assist device implantation.

Tarzia V, Buratto E, Bortolussi G, Paolini C, Bejko J, Bottio T, Gerosa G.

Artif Organs. 2015 Mar;39(3):248-53. doi: 10.1111/aor.12355. Review.

PMID:
25065398
Items per page

Supplemental Content

Support Center